LCM
CLDX icon

Laurion Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Laurion Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-290,850
Closed -$10.8M – 345
2024
Q2 		$10.8M Buy
290,850
+42,032
+17% +$1.59M 0.13% 107
2024
Q1 		$10.4M Buy
248,818
+110,287
+80% +$4.53M 0.09% 186
2023
Q4 		$5.49M Buy
+138,531
New +$4.07M 0.05% 237
2016
Q3 		– Sell
-987
Closed -$65K – 929
2016
Q2 		$65K Buy
+987
New +$62.7K ﹤0.01% 784
2015
Q3 		– Sell
-660
Closed -$250K – 745
2015
Q2 		$250K Buy
+660
New +$262K ﹤0.01% 545
2014
Q4 		– Sell
-1,127
Closed -$219K – 323
2014
Q3 		$219K Buy
+1,127
New +$246K ﹤0.01% 256

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return